Neurocrine Biosciences, Inc. (NBIX) Director Richard F. Pops Sells 5,500 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Richard F. Pops sold 5,500 shares of Neurocrine Biosciences stock in a transaction dated Monday, October 29th. The stock was sold at an average price of $107.13, for a total value of $589,215.00. Following the sale, the director now owns 37,759 shares in the company, valued at approximately $4,045,121.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

NASDAQ NBIX opened at $107.15 on Thursday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 9.19 and a current ratio of 9.19. Neurocrine Biosciences, Inc. has a 52-week low of $60.38 and a 52-week high of $126.98. The stock has a market cap of $9.70 billion, a P/E ratio of -66.14, a P/E/G ratio of 33.70 and a beta of 0.55.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Tuesday, July 31st. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.11. Neurocrine Biosciences had a negative return on equity of 14.22% and a negative net margin of 16.07%. The firm had revenue of $96.90 million for the quarter, compared to analyst estimates of $84.11 million. During the same quarter last year, the company posted ($0.68) earnings per share. The business’s revenue was up 1428.4% on a year-over-year basis. Analysts predict that Neurocrine Biosciences, Inc. will post 0.15 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. boosted its holdings in Neurocrine Biosciences by 643.7% in the 2nd quarter. Meeder Asset Management Inc. now owns 1,123 shares of the company’s stock valued at $110,000 after purchasing an additional 972 shares in the last quarter. TRUE Private Wealth Advisors purchased a new stake in Neurocrine Biosciences in the 3rd quarter valued at approximately $127,000. Steward Partners Investment Advisory LLC purchased a new stake in Neurocrine Biosciences in the 3rd quarter valued at approximately $127,000. Ladenburg Thalmann Financial Services Inc. boosted its holdings in Neurocrine Biosciences by 103.4% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,016 shares of the company’s stock valued at $167,000 after purchasing an additional 1,025 shares in the last quarter. Finally, Financial Architects Inc boosted its holdings in Neurocrine Biosciences by 283.7% in the 3rd quarter. Financial Architects Inc now owns 1,385 shares of the company’s stock valued at $170,000 after purchasing an additional 1,024 shares in the last quarter.

A number of analysts have recently commented on the company. Piper Jaffray Companies set a $115.00 target price on Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Friday, October 5th. Stifel Nicolaus lifted their target price on Neurocrine Biosciences from $137.00 to $142.00 and gave the stock a “buy” rating in a research report on Thursday, September 20th. Cantor Fitzgerald set a $150.00 target price on Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Thursday, September 20th. BidaskClub cut Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research report on Saturday, September 15th. Finally, Oppenheimer set a $140.00 price target on Neurocrine Biosciences and gave the stock a “buy” rating in a report on Wednesday, September 12th. One research analyst has rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $122.22.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.

Recommended Story: How Do You Calculate Return on Equity (ROE)?

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply